Peptide Targeted Gold Nanoplatform Carrying miR-145 Induces Antitumoral Effects in Ovarian Cancer Cells

Simple item page
dc.contributor.authorSalas-Huenuleo, Edison
dc.contributor.authorHernandez, Andrea
dc.contributor.authorLobos-Gonzalez, Lorena
dc.contributor.authorPolakovicova, Iva
dc.contributor.authorMorales-Zavala, Francisco
dc.contributor.authorAraya, Eyleen
dc.contributor.authorCelis, Freddy
dc.contributor.authorRomero, Carmen
dc.contributor.authorKogan, Marcelo J.
dc.date.accessioned2025-01-20T21:06:50Z
dc.date.available2025-01-20T21:06:50Z
dc.date.issued2022
dc.description.abstractOne of the recent attractive therapeutic approaches for cancer treatment is restoring downregulated microRNAs. They play an essential muti-regulatory role in cellular processes such as proliferation, differentiation, survival, apoptosis, cell cycle, angiogenesis, and metastasis, among others. In this study, a gold nanoplatform (GNPF) carrying miR-145, a downregulated microRNA in many cancer types, including epithelial ovarian cancer, was designed and synthesized. For targeting purposes, the GNPF was functionalized with the FSH33 peptide, which provided selectivity for ovarian cancer, and loaded with the miR-145 to obtain the nanosystem GNPF-miR-145. The GNPF-mir-145 was selectively incorporated in A2780 and SKOV3 cells and significantly inhibited cell viability and migration and exhibited proliferative and anchor-independent growth capacities. Moreover, it diminished VEGF release and reduced the spheroid size of ovarian cancer through the damage of cell membranes, thus decreasing cell viability and possibly activating apoptosis. These results provide important advances in developing miR-based therapies using nanoparticles as selective vectors and provide approaches for in vivo evaluation.
dc.fuente.origenWOS
dc.identifier.doi10.3390/pharmaceutics14050958
dc.identifier.eissn1999-4923
dc.identifier.urihttps://doi.org/10.3390/pharmaceutics14050958
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/93374
dc.identifier.wosidWOS:000803317300001
dc.issue.numero5
dc.language.isoen
dc.revistaPharmaceutics
dc.rightsacceso restringido
dc.subjectovarian cancer
dc.subjectnanoplatform
dc.subjectmicroRNA
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titlePeptide Targeted Gold Nanoplatform Carrying miR-145 Induces Antitumoral Effects in Ovarian Cancer Cells
dc.typeartículo
dc.volumen14
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas